^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    BCL2L2 overexpression

    i
    Other names: BCL2L2, BCL2 Like 2, Protein Phosphatase 1, Regulatory Subunit 51, BCLW, Apoptosis Regulator BCL-W, Apoptosis Regulator Bcl-W, Bcl-2-Like Protein 2, BCL2-L-2, Bcl2-L-2, KIAA0271, PPP1R51, BCL-W
    Entrez ID:
    599
    29d
    Tumor-derived miR-6794-5p enhances cancer growth by promoting M2 macrophage polarization. (PubMed, Cell Commun Signal)
    In this study, we identified changes in the tumor microenvironment caused by miR-6794-5p. Our study indicates that tumor-derived miR-6794-5p promotes tumor aggressiveness by inducing an immunosuppressive environment through interaction with macrophage.
    Journal
    |
    CD8 (cluster of differentiation 8) • JAK1 (Janus Kinase 1) • IL10 (Interleukin 10) • BCL2L2 (BCL2 Like 2) • SOCS1 (Suppressor Of Cytokine Signaling 1)
    |
    CD8 expression • BCL2L2 overexpression
    over3years
    Identification of Two Novel Circular RNAs Deriving from BCL2L12 and Investigation of Their Potential Value as a Molecular Signature in Colorectal Cancer. (PubMed, Int J Mol Sci)
    Interestingly, circ-BCL2L12-2 expression is inversely associated with TNM stage, while circ-BCL2L12-1 overexpression is associated with shorter overall survival in CRC, particularly among TNM stage II patients. Overall, we identified two novel BCL2L12 circRNAs, one of which can further stratify TNM stage II patients into two subgroups with substantially distinct prognosis.
    Journal
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    BCL2L2 overexpression
    over3years
    [VIRTUAL] Bclw Overexpression Predicts Aggressive Disease in B-Cell Lymphomas (ASH 2020)
    BCLW overexpression in aggressive B-cell lymphoma cell lines conferred resistance to the non-specific BH3 mimetic navitoclax as well as to venetoclax. Moreover, Cox regression analysis showed BCLW was an independent determinant of overall survival in DLBCL. Together, our results indicate that BCLW predicts for more aggressive disease in B-cell lymphomas and increased resistance to therapy.
    IO biomarker
    |
    MCL1 (Myeloid cell leukemia 1) • BCL2L1 (BCL2-like 1) • BCL2L2 (BCL2 Like 2)
    |
    BCL2L2 overexpression
    |
    Venclexta (venetoclax) • navitoclax (ABT 263)